Retrospective, single-centre, non-profit, observational study on pubertal development in patients with RASopathies. Literature data shows that puberty can be delayed by about 2 years in patients with RASopathies and this has been associated with a reduced peak growth rate. To date, only a few numerically limited case series without molecular characterisation have been published. This descriptive study should improve knowledge of pubertal development and its influence on growth and final stature. The primary aims are to describe the age of onset and progression of pubertal development in the cohort of patients with RASopathies, both male and female, and to describe the influence of pubertal development on statural growth and final stature in the same cohort.
Age range
8 Years – 35 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Age of pubertal onset in males and females in all different genotypes
Timeframe: at baseline
Proportion of males and females with delayed puberty in all different genotypes
Timeframe: at baseline
Age at the time of the presence of dosable serum LH (≥0,1 U/L) in males and females in all different genotypes
Timeframe: at baseline
Age at time of presence of dosable serum estradiol (>15 pg/ml) in females in all different genotypes
Timeframe: at baseline
Age at time of presence of dosable serum testosterone (>0,2 ng/ml) in males in all different genotypes
Timeframe: at baseline
Age of reaching Peak Height Velocity in males and females in all different genotypes
Timeframe: at baseline
Statural gain at puberty in males and females in all different genotypes
Timeframe: at baseline
Peak Height Velocity in males and females in all different genotypes
Timeframe: at baseline